Literature DB >> 20956604

Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

J M Entenza1, T R Veloso, J Vouillamoz, M Giddey, P Moreillon.   

Abstract

Continuous infusion of vancomycin was evaluated against experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Animals were infected with hVISA PC1 (vancomycin MIC, 2 mg/liter) or VISA PC3 (vancomycin MIC, 8 mg/liter) and treated for 5 days with constant serum levels of 20 or 40 mg/liter. Vancomycin continuous infusion was unsuccessful, as 20 mg/liter was barely active against PC1 (6 of 13 sterile vegetations) and 40 mg/liter failed against PC3 (2 of 9 sterile vegetations).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20956604      PMCID： PMC3019629          DOI： 10.1128/AAC.00811-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; Willam A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

2.  Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.

Authors:  Young Kyung Yoon; Jeong Yeon Kim; Dae Won Park; Jang Wook Sohn; Min Ja Kim
Journal:  J Antimicrob Chemother       Date:  2010-03-03       Impact factor: 5.790

3.  Natural history of aortic valve endocarditis in rats.

Authors:  E Héraïef; M P Glauser; L R Freedman
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

4.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

5.  Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats.

Authors:  U Fluckiger; P Moreillon; J Blaser; M Bickle; M P Glauser; P Francioli
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.

Authors:  Paul R Ingram; David C Lye; Paul A Tambyah; Wei P Goh; Vincent H Tam; Dale A Fisher
Journal:  J Antimicrob Chemother       Date:  2008-03-10       Impact factor: 5.790

8.  Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.

Authors:  Federico Pea; Mario Furlanut; Camilla Negri; Federica Pavan; Massimo Crapis; Francesco Cristini; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 9.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.

Authors:  Thomas P Lodise; Nimish Patel; Ben M Lomaestro; Keith A Rodvold; George L Drusano
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079
View more
  6 in total

1.  Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Federico Pea; Piergiorgio Cojutti; Nicola Petrosillo; Mario Furlanut; J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-09       Impact factor: 5.191

2.  Management of MRSA/GISA, VISA Endocarditis.

Authors:  Cédric Jacqueline; Jocelyne Caillon; David Boutoille
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

3.  A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.

Authors:  Karla D Passalacqua; Sarah W Satola; Emily K Crispell; Timothy D Read
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

4.  Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis.

Authors:  F Campanile; D Bongiorno; M Falcone; F Vailati; M B Pasticci; M Perez; A Raglio; F Rumpianesi; C Scuderi; F Suter; M Venditti; C Venturelli; V Ravasio; M Codeluppi; S Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-07       Impact factor: 3.267

5.  Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.

Authors:  Yuki Katayama; Takuya Azechi; Motoyasu Miyazaki; Tohru Takata; Miwa Sekine; Hidehito Matsui; Hideaki Hanaki; Koji Yahara; Hiroshi Sasano; Kota Asakura; Tomoiku Takaku; Tomonori Ochiai; Norio Komatsu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Infective Endocarditis.

Authors:  Jonathan Save; Yok-Ai Que; José Entenza; Grégory Resch
Journal:  Viruses       Date:  2022-08-16       Impact factor: 5.818
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.